External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience CHARCOT 2023
Roche and Genentech at

CHARCOT 2023

November 09 - November 11
Baveno, Italy
charcot-ms.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 27 / Roche
Watch: Federated Architecture and Learning: Are we on the Cusp of a New (Approach To) Understanding Biological and Clinical Data?
An interactive symposium where the expert panel navigate the paradigm shift of hypothesis-driven research to data-driven research with machine learning, federated architecture and federated learning. The faculty discuss how these concepts can be utilised to accelerate our understanding of multimodal big data across MS and introduced INTONATE-MS, a federated architecture to drive collaborative research between academia and industry.(Full recording).
Neuroscience Multiple Sclerosis CHARCOT-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 27 / Roche
Federated Architecture and Learning: Are we on the Cusp of a New (Approach To) Understanding Biological and Clinical Data?
An interactive symposium where the expert panel navigate the paradigm shift of hypothesis-driven research to data-driven research with machine learning, federated architecture and federated learning. The faculty discuss how these concepts can be utilised to accelerate our understanding of multimodal big data across MS and introduced INTONATE-MS, a federated architecture to drive collaborative research between academia and industry. (Symposium slides).
Neuroscience Multiple Sclerosis CHARCOT-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Cerebrospinal Fluid and MRI Analyses of Fenebrutinib Treatment in Multiple Sclerosis Reveal Brain Penetration and Early Reduction of New Lesion Activity: Results from the Phase II FENopta study
Bruton’s tyrosine kinase (BTK) is implicated in peripheral and central nervous system inflammation in multiple sclerosis (MS) and is a therapeutic target for relapsing and progressive disease. Fenebrutinib is a potent, highly selective, noncovalent, reversible BTK inhibitor under investigation for MS. The objective of FENopta, a randomised, double-blind, placebo-controlled, Phase 2 trial (NCT05119569), was to evaluate efficacy and safety of fenebrutinib in relapsing MS and evaluate the early impact of fenebrutinib on MRI outcomes and soluble markers of disease activity and progression.
Neuroscience Multiple Sclerosis CHARCOT-2023
11:30 AM
Duration 60mins Baveno, Italy
Cerebrospinal Fluid and MRI Analyses of Fenebrutinib Treatment in Multiple Sclerosis Reveal Brain Penetration and Early Reduction of New Lesion Activity: Results from the Phase II FENopta study
Amit Bar-Or, Michal Dufek, Hrvoje Budincevic, Jelena Drulovic, Mario Habek, Le H Hua, Martin S Weber, Piia Thomas, Julie Napieralski, David Clayton, Denison Kuruvilla, Qi Qi, Yan Xu, Alexandra Goodyear, Jiwon Oh
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:15 PM
Duration 5mins Baveno, Italy
Federated Architecture and Learning: Are we on the cuspo of a New (Approach To) Understanding Biological and Clinical Data?
Jiwon Oh, Heinz Wiendl
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.